Computerized Addiction Prevention for Opioid Prescribing

阿片类药物处方的计算机化成瘾预防

• 批准号: 6832985
• 负责人: JOSHUA HORWITZ
• 金额: $ 9.84万
• 依托单位: WATERFORD LIFE SCIENCES
• 依托单位国家: 美国
• 财政年份: 2004
• 资助国家: 美国
• 起止时间: 2004-08-15 至 2005-02-14
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6832985
• 关键词: behavioral /social science research tag; clinical research; computer assisted medical decision making; computer program /software; computer system design /evaluation; drug abuse prevention; drug tolerance; human subject; interview; opiate alkaloid; patient care personnel relations; patient care planning; self medication; therapy compliance

DESCRIPTION (provided by applicant): This Phase I application proposes to test the feasibility of AESOP (Assessment and Evaluation for Safe Opioid Prescribing), an integrated suite of software tools that will enable primary care physicians to prevent prescription drug abuse and addiction during long-term opioid therapy. Currently there is no interactive software incorporating validated assessment and treatment protocols for pain management with opioids. AESOP will serve this growing and umet need by offering primary care physicians a computer-assisted algorithm to: (1) assess patients for opioid therapy based on a detailed personal, medical and pain management history (2) identify patients at high risk for addiction or abuse (3) educate patients about risks and benefits of long-term opioid therapy (4) institute waiting periods to discourage "doctor-shopping" and illicit drug-seeking, (5) implement customized doctor-patient agreements to increase adherence and minimize abuse and diversion, (6) monitor patients at subsequent prescribing visits via in-depth assessment of functional measures that indicate tolerance, addiction, diversion, or abuse. AESOP's evidence-based risk-reduction and transparency will benefit physicians, patients, insurers, and state and federal regulators who monitor Schedule II prescribing. And AESOP will be highly valuable to pharmaceutical companies; as the first computerized learning tool for opioid prescribing, AESOP can be play a central role in Risk Management Plans that opioid manufacturers must develop and deploy in order to win FDA approval for any new opioids. Phase I goals include: 1) Clinical research to validate the centerpiece of AESOP, a computer-assisted physician-patient agreement that governs the prescribing relationship and establishes functional goals for the patient, and 2) In-depth interviews with primary care physicians to ensure that the product's design specifications will conform to existing primary care technology and practice infrastructure. Phase II will develop a beta version of AESOP which can be tested and validated in a primary care setting.

描述（由申请人提供）：本I阶段申请建议测试AESOP的可行性（评估和评估阿片类药物处方），这是一套综合的软件工具套件，可以使初级保健医生在长期治疗期间防止处方药物滥用和成瘾。当前，没有交互式软件，其中包含经过验证的评估和治疗方案，用于使用阿片类药物进行疼痛管理。 AESOP将通过向初级保健医生提供一种计算机辅助算法来满足这一不断增长的需求：（1）根据详细的个人，医疗和疼痛管理历史（2）确定成瘾或虐待风险高的患者（3）对患者（3）对患者进行高度疗法的风险和益处（4）Interiment opections and Shiosseks and Shiot（4） （6）通过深入评估表明宽容，成瘾，转移或虐待的功能措施，以随后的处方访问来监视患者，以增加滥用和转移，以增加依从性并最大程度地减少滥用和转移。 AESOP的基于证据的降低风险和透明度将使监控附表II处方的医师，患者，保险公司以及州和联邦监管机构受益。 Aesop对制药公司将非常有价值；作为第一个用于阿片类药物处方的计算机学习工具，AESOP可以在阿片类药物制造商必须开发和部署的风险管理计划中发挥核心作用，以赢得任何新阿片类药物的FDA批准。第一阶段的目标包括：1）临床研究以验证AESOP的核心，这是一项由计算机辅助的医师患者协议，该协议控制着处方关系并为患者建立功能目标，以及2）与初级保健医生的深入访谈，以确保产品的指定规格符合现有的初级护理技术和实践基础构造。第二阶段将开发AESOP的Beta版本，可以在初级保健环境中进行测试和验证。